Get notified of page updates

A Study of Nivolumab in Selected Uterine Cancer Patients

Clinicaltrials.gov identifier:
NCT03241745

Study Contact Information:

Principal Investigator:
Claire Friedman, MD
by phone: 646-888-4247 or by email  

PRINTER FRIENDLY PAGE
Overview
Who Can Join
Contact
Glossary on
off

About the Study

The purpose of this study is to test the effectiveness, safety, and tolerability of Nivolumab on patients with or recurrent uterine cancer. 

Nivolumab is a type of known as an immune checkpoint inhibitor. Immune checkpoint inhibitors are drugs that prevent cancer cells from switching off immune cells. This allows the immune system to find, unmask and destroy cancer cells.  NOTE: This study is no longer enrolling. 

 

This Study is Open To:

NOTE: This study is no longer enrolling. 

This Study is NOT Open To:

NOTE: This study is no longer enrolling. 

Study Contact Information:

Principal Investigator:
Claire Friedman, MD
by phone: 646-888-4247 or by email  

Clinicaltrials.gov identifier:
NCT03241745

Study Contact Information:

Principal Investigator:
Claire Friedman, MD
by phone: 646-888-4247 or by email  

PRINTER FRIENDLY PAGE